Drug Trial Radar · NCT01747577
Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)
Last checked: Nov 20, 2026Latest source record: Nov 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
68
Actual
Start
Dec 4, 2012
Primary completion
Oct 24, 2013
Study completion Oct 24, 2013
Sponsor
- Lead sponsor
- Astellas Pharma Korea, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Dec 11, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate superiority of the solifenacin succinate (treatment) over the placebo (control) based on the change from the baseline in the mean number of urgency episodes per 24 hours after 2 weeks.
Conditions
- Overactive Bladder
- Benign Prostate Hyperplasia
- Transurethral Resection of Prostate
- Photoselective Vaporization Prostatectomy
Interventions
Solifenacin SuccinateDrug
Oral
PlaceboDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from the baseline in the number of urgency episodes per 24 hrs in the voiding diary at Week 2Time frame: Baseline and at week 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.